By Josh White
Date: Tuesday 08 Oct 2024
(Sharecast News) - Fusion Antibodies reported positive trading in an update on Tuesday, highlighting significant progress for the first half of its financial year.
By Josh White
Date: Thursday 05 Sep 2024
(Sharecast News) - Preclinical antibody discovery and engineering specialist Fusion Antibodies said in its final results on Thursday that despite a challenging year with a decline in revenue, it had strengthened its financial position and expanded its pipeline of opportunities.
By Iain Gilbert
Date: Thursday 04 Jul 2024
(Sharecast News) - Antibody discovery specialist Fusion Antibodies said on Thursday that it was both "on track and on plan" following "positive momentum" throughout Q1.
Currency | UK Pounds |
Share Price | 4.20p |
Change Today | -0.050p |
% Change | -1.18 % |
52 Week High | 7.20 |
52 Week Low | 2.90 |
Volume | 411,078 |
Shares Issued | 95.95m |
Market Cap | £4.03m |
Beta | 0.51 |
RiskGrade | 464 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:08 | 6,835 @ 4.10p |
14:54 | 75,000 @ 4.11p |
12:57 | 22 @ 4.40p |
12:56 | 559 @ 4.11p |
11:42 | 11,271 @ 4.33p |
Chair | Simon Gordon Douglas |
CEO | Adrian Kinkaid |
You are here: research